Galectin-3 Regulates Differentiation and Atrophy of Skeletal Muscle via TGFβ/Smad Signaling in Mice

Xueying Ji,Mengjuan Xue,Xin Jiang,Fan Zhang,Huiyuan Yu,Xiaona Hu,Fan Yang,Zhijun Bao
DOI: https://doi.org/10.2139/ssrn.3453322
2019-01-01
Abstract:Background: Skeletal muscle is the dominant organ system in locomotion and energy metabolism. Accumulating evidence has revealed the pivotal role of endogenous glucocorticoids in the pathogenesis of skeletal muscle loss. However, to date, the possible molecular mechanisms underlying are not yet fully understood. Methods: Glucocorticoids-induced muscle atrophy model was built to detect the expression of galectin-3 in vivo and in C2C12 cell lines. Loss-of-function experiments were applied to determine the cellular functions of galectin-3 in in vivo and in C2C12 cells. Real-time qPCR, western blotting, immunofluorescence, H&E staining, and co-immunoprecipitation were performed to uncover the potential mechanism concerning galectin-3 during skeletal muscle biology. The relevance of the findings was confirmed in mice muscle and blood samples. Findings: Galectin-3 was identified as a remarkable up-regulated gene during skeletal muscle loss. The overexpression character of galectin-3 was confirmed in GC-induced atrophy mice model and C2C12 muscle cells. In vitro galectin-3 knockdown promoted the myogenic differentiation and proliferation capacity of C2C12 myoblasts, and prevented the atrophy of fully differentiated myotubes. In established GC-induced mice model, galectin-3 inhibition suppressed muscle atrophy progression, and recovered muscle mass, with enlarged number and cross-sectional area of skeletal muscle fibers, as well as a dramatic decrease in serum myostatin concentration. A search for the molecular mechanism revealed that galectin-3 results in increased the expression of TGFβ1 and TGFβR-I, which affected Smad2, 3 phosphorylation and subsequently mediated skeletal muscle reduction by activating Smad2/3 signaling pathways. Interpretation: Galectin-3 facilitates TGFβ1 and TGFβR-I transcription, thus activating TGFβ/Smad signaling pathways in myoblasts, contributing to myogenesis inhibition and atrophy exacerbation, further, skeletal muscle loss. Funding Statement: The research was supported by grants from the National Key Research and Development Program of China (No: 2018YFC2002000), the National Natural Science Foundation of China (No: 81701374 and 81901408), Shanghai Medical Leadership Training Program (No: 2019LJ09), Shanghai Sailing program (No: 19YF1414500 and 17YF1405200), Shanghai Municipal Science and Technology Committee Program (No: YDZX20173100004026), Young Excellent Medical Talents Training Program of Health Department of Shanghai Municipal Government (No: 2018YQ58). Declaration of Interests: Authors have no conflicts of interest. Ethics Approval Statement: All animals received humane care according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985), and the experimental protocol was reviewed and approved by the ethical committees of School of Life Science, Fudan University.
What problem does this paper attempt to address?